The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
A superparamagnetic iron oxide nanoparticle coated with a low molecular
weight semi-synthetic carbohydrate, polyglucose sorbitol carboxymethyl
ether, with potential anti-anemic and imaging properties. After
intravenous administration, ferumoxytol replaces iron stores with fewer
side effects compared to the use of oral iron. In addition, this agent
generates T1 relaxation, producing a magnetic field and enhancing T2
relaxation, thereby darkening contrast media-containing structures in
magnetic resonance imaging (MRI). Due to small particle size,
ferumoxytol remains in the intravasculature for a prolonged period and
so may be used as a blood pool agent.